Microbix Biosystems (MBX) investor relations material

Diagnostics platform and markets

• Antigens provide purified, inactivated pathogens for infectious-disease tests; quality controls mimic patient samples to verify test accuracy.

• Products support millions to tens of millions of tests; customers include Abbott, Becton Dickinson, Roche, Cepheid, Danaher, CAP, API and Labquality.

• More than 95% of sales are exports, across the U.S., Western Europe, Scandinavia, Australia, the Indo-Pacific and a growing South American presence.

• Growing direct sales to clinical labs and point-of-care settings; controls can be supplied as liquids, swabs or tissue mimetics for diverse testing applications.

• Industry tailwinds include more rigorous test regulation and expanding molecular diagnostics, including PCR-based HPV screening and synthetic reference materials for RNA-virus tests.

Growth initiatives and infrastructure

• Three Mississauga facilities, 120 staff and capacity to manufacture ~400 products; existing infrastructure supports operating leverage as production runs scale.

• Working with multinational diagnostics firms on next-generation assays, including controls embedded in liquid vials, swabs and test cartridges.

• In September, qualified as an audited supplier with five of the 10 largest diagnostics companies, positioning for large projects; major partner opportunities targeted in coming months.

• Growth plans include expanding existing accounts, adding customers, broadening the product portfolio and entering new markets.

• QUANTDx reference samples help developers quantify test signals and refine results; potential uses include assay development and controls inside individual cartridges.

Financial position and outlook

• FY2026 revenue expected at CAD 16.5M–17M after two clients were lost in the same quarter in mid-2025; revenue recovery is underway.

• Break-even revenue is ~CAD 22M, with a modest current burn rate; management cited a strong balance sheet and built-out operating capacity.

• Larger manufacturing runs are expected to expand margins; growth plans leverage current relationships, capacity and capabilities.